Kintara Therapeutics (NASDAQ:KTRA) Earns Buy Rating from Analysts at Aegis

Aegis initiated coverage on shares of Kintara Therapeutics (NASDAQ:KTRA) in a research report report published on Monday, The Fly reports. The firm issued a buy rating and a $6.00 price target on the stock.

Shares of NASDAQ KTRA opened at $1.60 on Monday. Kintara Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $1.95.

Kintara Therapeutics Company Profile

Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma.

Further Reading: Overbought

The Fly

Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.